BRPI0916560A2 - análogo de insulina, ácido nucléico, vetor de expressão, célula hospedeira e método de tratamento de um paciente. - Google Patents

análogo de insulina, ácido nucléico, vetor de expressão, célula hospedeira e método de tratamento de um paciente.

Info

Publication number
BRPI0916560A2
BRPI0916560A2 BRPI0916560A BRPI0916560A BRPI0916560A2 BR PI0916560 A2 BRPI0916560 A2 BR PI0916560A2 BR PI0916560 A BRPI0916560 A BR PI0916560A BR PI0916560 A BRPI0916560 A BR PI0916560A BR PI0916560 A2 BRPI0916560 A2 BR PI0916560A2
Authority
BR
Brazil
Prior art keywords
patient
treatment
nucleic acid
host cell
expression vector
Prior art date
Application number
BRPI0916560A
Other languages
English (en)
Inventor
Michael Weiss
Original Assignee
Univ Case Western Reserve
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Case Western Reserve filed Critical Univ Case Western Reserve
Publication of BRPI0916560A2 publication Critical patent/BRPI0916560A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Obesity (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
BRPI0916560A 2008-07-31 2009-07-31 análogo de insulina, ácido nucléico, vetor de expressão, célula hospedeira e método de tratamento de um paciente. BRPI0916560A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8521208P 2008-07-31 2008-07-31
PCT/US2009/052477 WO2010014946A2 (en) 2008-07-31 2009-07-31 Halogen-stabilized insulin

Publications (1)

Publication Number Publication Date
BRPI0916560A2 true BRPI0916560A2 (pt) 2015-11-10

Family

ID=41610982

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0916560A BRPI0916560A2 (pt) 2008-07-31 2009-07-31 análogo de insulina, ácido nucléico, vetor de expressão, célula hospedeira e método de tratamento de um paciente.

Country Status (14)

Country Link
EP (2) EP2982687A1 (pt)
JP (2) JP5780958B2 (pt)
KR (1) KR20110061552A (pt)
CN (1) CN102171245B (pt)
AU (1) AU2009276346B2 (pt)
BR (1) BRPI0916560A2 (pt)
CA (1) CA2732439A1 (pt)
ES (1) ES2552636T3 (pt)
HK (1) HK1161275A1 (pt)
MX (1) MX2011001181A (pt)
MY (1) MY158627A (pt)
NZ (1) NZ590792A (pt)
RU (1) RU2555557C2 (pt)
WO (1) WO2010014946A2 (pt)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007081824A2 (en) 2006-01-06 2007-07-19 Case Western Reserve University Fibrillation resistant proteins
WO2008043033A2 (en) 2006-10-04 2008-04-10 Case Western Reserve University Fibrillation-resistant insulin and insulin analogues
US8993516B2 (en) 2008-04-14 2015-03-31 Case Western Reserve University Meal-time insulin analogues of enhanced stability
KR20120129875A (ko) 2008-07-31 2012-11-28 케이스 웨스턴 리저브 유니버시티 염소화 아미노산을 갖는 인슐린 유사체
US9200053B2 (en) 2008-07-31 2015-12-01 Case Western Reserve University Insulin analogues containing penta-fluoro-Phenylalanine at position B24
CA2732439A1 (en) * 2008-07-31 2010-02-04 Case Western Reserve University Halogen-stabilized insulin
AU2008365559B2 (en) 2008-12-15 2016-02-25 Zealand Pharma A/S Glucagon analogues
JP5635531B2 (ja) 2008-12-15 2014-12-03 ジーランド ファーマ アクティーゼルスカブ グルカゴン類似体
WO2010070251A1 (en) 2008-12-15 2010-06-24 Zealand Pharma A/S Glucagon analogues
DK2370460T3 (da) 2008-12-15 2014-08-04 Zealand Pharma As Glucagon analoger
ES2537287T3 (es) 2009-07-13 2015-06-05 Zealand Pharma A/S Análogos de glucagón acilados
US8399407B2 (en) 2009-09-17 2013-03-19 Case Western Reserve University Non-standard insulin analogues
MY189079A (en) * 2009-12-11 2022-01-25 Univ Case Western Reserve Insulin analogues with chlorinated amino acids
UY33462A (es) 2010-06-23 2012-01-31 Zealand Pharma As Analogos de glucagon
CN103068841A (zh) 2010-06-24 2013-04-24 西兰制药公司 胰高血糖素类似物
PE20140969A1 (es) 2011-01-20 2014-07-24 Zealand Pharma As Combinacion de analogos del glucagon acilados con analogos de insulina
US10995129B2 (en) * 2011-07-13 2021-05-04 Case Western Reserve University Non-standard insulin analogues
US9487572B2 (en) * 2011-07-13 2016-11-08 Case Western Reserve University Non-standard insulin analogues
BR112014010139A2 (pt) * 2011-10-27 2017-04-25 Univ Case Western Reserve formulação farmacêutica, método de redução do nível de açúcar no sangue de um paciente e polipeptídeo
EP2804621A4 (en) * 2012-01-20 2015-11-18 Univ Case Western Reserve GLUTAMINE-SAFE STABILIZED INSULIN ANALOG
EP2844669B1 (en) 2012-05-03 2018-08-01 Zealand Pharma A/S Gip-glp-1 dual agonist compounds and methods
AU2013295035B2 (en) 2012-07-23 2017-08-03 Zealand Pharma A/S Glucagon analogues
TWI608013B (zh) 2012-09-17 2017-12-11 西蘭製藥公司 升糖素類似物
KR20150110677A (ko) * 2013-01-22 2015-10-02 케이스 웨스턴 리저브 유니버시티 N 말단 절단된 인슐린 유사체
JP2016516728A (ja) * 2013-03-15 2016-06-09 ケース ウェスタン リザーブ ユニバーシティＣａｓｅ Ｗｅｓｔｅｒｎ Ｒｅｓｅｒｖｅ Ｕｎｉｖｅｒｓｉｔｙ 第２部位インスリン類似体
RS57632B1 (sr) 2013-10-17 2018-11-30 Zealand Pharma As Acilovani analozi glukagona
US9988429B2 (en) 2013-10-17 2018-06-05 Zealand Pharma A/S Glucagon analogues
AU2014345569B2 (en) 2013-11-06 2020-08-13 Zealand Pharma A/S GIP-GLP-1 dual agonist compounds and methods
EP3066117B1 (en) 2013-11-06 2019-01-02 Zealand Pharma A/S Glucagon-glp-1-gip triple agonist compounds
WO2015106269A2 (en) * 2014-01-13 2015-07-16 Thermalin Diabetes, Llc Rapid action insulin formulations and pharmaceutical delivery systems
CA2961037A1 (en) 2014-10-06 2016-04-14 Case Western Reserve University Biphasic single-chain insulin analogues
EP3985016A1 (en) 2014-10-29 2022-04-20 Zealand Pharma A/S Gip agonist compounds and methods
EP3247720A4 (en) * 2015-01-20 2018-06-06 Case Western Reserve University Insulin analogues with selective signaling properties and reduced mitogenicity
EP3283507B8 (en) 2015-04-16 2019-11-13 Zealand Pharma A/S Acylated glucagon analogue
EA039101B1 (ru) * 2015-12-23 2021-12-03 Кейс Вестерн Ризерв Юниверсити Капсулирование ультрастабильных аналогов инсулина в полимерных расплавах
RU2769476C2 (ru) * 2016-07-22 2022-04-01 Университи Оф Юта Ресёч Фаудэтион Аналоги инсулина
EP3506906A4 (en) * 2016-08-31 2020-08-12 Taro Pharmaceutical Industries Ltd. TOPICAL FENOLDOPAM FORMULATIONS FOR THE TREATMENT OF SKIN DISEASES
CN113543773B (zh) 2019-03-08 2023-07-14 塔罗制药工业有限公司 稳定的局部用非诺多泮组合物
EP4326311A1 (en) * 2021-04-22 2024-02-28 The United States of America, as represented by the Secretary, Department of Health and Human Services Human insulin c-alpha-peptides and methods of use

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03506023A (ja) 1988-07-20 1991-12-26 ノボ　ノルデイスク　アクツイエセルスカプ ポリペプチド
US5474978A (en) 1994-06-16 1995-12-12 Eli Lilly And Company Insulin analog formulations
UA72427C2 (en) * 1996-06-20 2005-03-15 Novo Nordisk As Water-soluble insulin preparation containing mannite, method for manufacturing composition containing soluble insulin or crystalline insulin
DE19825447A1 (de) * 1998-06-06 1999-12-09 Hoechst Marion Roussel De Gmbh Neue Insulinanaloga mit erhöhter Zinkbildung
US7316999B2 (en) * 2000-06-02 2008-01-08 Novo Nordisk A/S Glucose dependent release of insulin from glucose sensing insulin derivatives
AU2002346490A1 (en) * 2001-12-20 2003-07-09 Eli Lilly And Company Insulin molecule having protracted time action
WO2007081824A2 (en) 2006-01-06 2007-07-19 Case Western Reserve University Fibrillation resistant proteins
WO2008043033A2 (en) 2006-10-04 2008-04-10 Case Western Reserve University Fibrillation-resistant insulin and insulin analogues
CA2732439A1 (en) * 2008-07-31 2010-02-04 Case Western Reserve University Halogen-stabilized insulin

Also Published As

Publication number Publication date
AU2009276346B2 (en) 2014-07-03
HK1161275A1 (en) 2012-08-24
EP2318432B1 (en) 2015-09-02
EP2318432A4 (en) 2012-02-29
JP5780958B2 (ja) 2015-09-16
MY158627A (en) 2016-10-31
EP2982687A1 (en) 2016-02-10
NZ590792A (en) 2012-12-21
JP2011529692A (ja) 2011-12-15
RU2555557C2 (ru) 2015-07-10
EP2318432A2 (en) 2011-05-11
KR20110061552A (ko) 2011-06-09
ES2552636T3 (es) 2015-12-01
CN102171245A (zh) 2011-08-31
CN102171245B (zh) 2015-03-25
AU2009276346A1 (en) 2010-02-04
WO2010014946A2 (en) 2010-02-04
WO2010014946A3 (en) 2010-05-20
RU2011106744A (ru) 2012-09-10
CA2732439A1 (en) 2010-02-04
JP2015180647A (ja) 2015-10-15
MX2011001181A (es) 2011-04-05

Similar Documents

Publication Publication Date Title
BRPI0916560A2 (pt) análogo de insulina, ácido nucléico, vetor de expressão, célula hospedeira e método de tratamento de um paciente.
BRPI0911571A2 (pt) método para tratar um mamífero, análogo de insulina, ácido nucléico e célula hospedeira
BRPI1012642A2 (pt) formulação de insulina e método para o tratamento de um indivíduo diabético.
BR112012024287A2 (pt) anticorpo, composição farmacêutica, método, ácido nucleico, vetor de expressão e célula hospedeira
IL195081A0 (en) Acquisition of malicious code using active learning
BRPI0920026A2 (pt) método de tratamento de infecção pulmonar, composição farmacêutica e respectivos usos.
EP2344218A4 (en) HEART SUPPORT PUMP, SYSTEM AND METHOD
BRPI1014760A2 (pt) preparacao compreendendo insulina, nicotinamida e um aminoacido
BRPI1007996A2 (pt) fluido de tratamento, e, método
EP2184687A4 (en) COMPILATION SYSTEM FOR REGULAR EXPRESSIONS, TUNING SYSTEM, COMPILING METHOD AND TUNING PROCEDURE
AP2010005462A0 (en) Harmful organism control composition, and method for control of harmful organisms.
BRPI1006215A2 (pt) " anticorpos multiespecíficos, ácido nucleico, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica, método de tratamento, método de inibição de uma atividade bíologica e uso do anticorpo "
WO2012046084A3 (en) Short rna molecules
IL207558A0 (en) Pharmaceutical solutions, process of prepartion and therapeutic uses
DK2376015T3 (da) Pneumopedisk-ortodontisk instrument, system og fremgangsmåde.
EP2631291A4 (en) NUCLEIC ACID MOLECULES INDUCING RNA INTERFERENCE, AND USES THEREOF
BR112013015129A2 (pt) anticorpo isolado ou fragmento do mesmo, composição farmacêutica, método para imunização passiva, método para tratamento de uma infecção pelo vírus da dengue, método para produzir um anticorpo de neutralização contra um vírus da dengue, ácido nucleico isolado, vetor de expressão e célula hospedeira
ITBO20060735A1 (it) Calotta per il trattamento della pelle e del derma.
BRPI0812865A2 (pt) Derivados de 6-anilinopurina substituída como inibidores de citoquinina oxidase/desidrogenase e preparações contendo esses derivados.
EP2362179A4 (en) OPTICAL SYSTEM, METHOD AND COMPUTER PROGRAM FOR DETECTING THE PRESENCE OF A LIVING BIOLOGICAL ORGANISM
EP2482645A4 (en) Method, device and fluid for treatment of a heart after harvesting
BR112012027545A2 (pt) composto de fórmula i, composição farmacêutica, uso da composição farmacêutica, uso de um composto e método de modulação do nível de glicose no sangue em um indivíduo
AP2010005443A0 (en) Antiviral drugs for treatment of arenavirus infection.
IL192333A0 (en) Photobioreactor, system and method for the cultivation of microalgae
WO2011115809A3 (en) High energy radiation insensitive analyte sensors

Legal Events

Date Code Title Description
B08F Application fees: dismissal - article 86 of industrial property law

Free format text: REFERENTE A 7A ANUIDADE.

B08K Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87)

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2384 DE 13-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.